# Berberine Liver Enzymes Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/berberine-liver-enzymes-meta-analysis-evidence-review
Category: evidence-review
Summary: Berberine Liver Enzymes Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are s
Last reviewed: 2026-07-29
Reviewed by: Migaku Evidence Review
# Berberine Liver Enzymes Meta-analysis: What the Evidence Says

## Quick Answer

Berberine Liver Enzymes Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| A Systematic Review of Herbal Medicines in the Management of Diabetes: Efficacy, Toxicological Profiles, and Clinical Safety Considerations | systematic review | 1 | 2026-04-23 | 10.7759/cureus.107618 |
| TCM-Derived Natural Compounds Targeting the Gut Microbiota in Metabolic Dysfunction-Associated Steatotic Liver Disease: Gut–Liver Axis Mechanisms, Safety Considerations, and Translational Challenges | preclinical study | 4 | 2026-05-19 | 10.3390/metabo16050342 |

## What The Sources Report

- Prediabetes is defined as an intermediate metabolic state characterized by impaired fasting glucose and/or impaired glucose tolerance, associated with a high risk of progression to diabetes and vascular dysfunction. [Muacevic Alexander (2026); evidence level 1]
- However, long-term use of conventional antidiabetic agents has been associated with adverse effects, reduced tolerance, and diminished efficacy in certain populations. [Muacevic Alexander (2026); evidence level 1]
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is a subtype of steatotic liver disease (SLD) defined by the presence of hepatic steatosis together with at least one cardiometabolic risk factor after exclusion of other dominant causes of steatosis. [Deng Huailin (2026); evidence level 4]
- Its disease spectrum includes simple steatosis, metabolic dysfunction-associated steatohepatitis (MASH), liver fibrosis, cirrhosis, and even hepatocellular carcinoma. [Deng Huailin (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For berberine liver enzymes meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Muacevic Alexander (2026). A Systematic Review of Herbal Medicines in the Management of Diabetes: Efficacy, Toxicological Profiles, and Clinical Safety Considerations. DOI: 10.7759/cureus.107618. PMCID: PMC13198626. PMID: 42186642. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13198626/
- Deng Huailin (2026). TCM-Derived Natural Compounds Targeting the Gut Microbiota in Metabolic Dysfunction-Associated Steatotic Liver Disease: Gut–Liver Axis Mechanisms, Safety Considerations, and Translational Challenges. DOI: 10.3390/metabo16050342. PMCID: PMC13209097. PMID: 42188051. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13209097/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.